Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs NuBloom

Kin Meds
Graded #73

Higher grade

vs+3.9000000000000057
NuBloom
Graded #134

Lower grade

The verdict

Kin Meds takes it — 72.9/100 to 69/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +2
74
72
Dose & formulationKin Meds +39
93
54
Clinical oversightNuBloom +8
74
82
Labs & monitoringNuBloom +8
53
61
FulfillmentNuBloom +13
72
85
Contract termsEven
55
55
Kin Meds · left barNuBloom · right bar

The numbers

MetricKin MedsNuBloom
WeighScore72.9/10069/100
GradeCC
Scorecard rank#73#134
Semaglutide$149/mo (brand Wegovy)$149/mo (2.4 mg dose, compounded)
Tirzepatide$149/mo (brand Zepbound)$279/mo (15 mg dose, compounded)
CoverageCoverage not published49 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Kin Meds

Graded #73 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described
NuBloom

Graded #134 · C

Strengths

  • Transparent, openly published pricing: compounded semaglutide $149/mo and tirzepatide $279/mo as flexible month-to-month subscriptions
  • Founded and medically led by a named physician (Dr. Marianne Pinkston Mueller, family/integrative medicine, 25+ years)
  • Whole-person model pairs GLP-1s with hormone, gut-health and longevity care plus in-depth lab testing
  • State coverage published openly: 49 states listed on the site (all except Mississippi)
  • Optional 90-day 1:1 coaching program with weekly meetings and unlimited text support ($599/mo)

Where it loses points

  • Compounding pharmacy partners are not named anywhere on the site — a transparency gap
  • NuBloom's own LegitScript/PCAB status is not displayed; only its telehealth partner is certified
  • Compounded medications are not FDA-approved; one FAQ loosely calls them 'FDA-approved,' contradicting the product pages
  • All sales are final and medical consult fees are non-refundable; no returns on prescription products
  • Disputes go to binding individual arbitration; the Terms' governing-law state is left as an unfilled '[STATE]' placeholder

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard